A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.
A drug being tested by scientists at China’s prestigious Peking University could not only shorten the recovery time for those infected but even offer short-term immunity from the virus, researchers say.
Sunney Xie, director of the university’s Beijing Advanced Innovation Center for Genomics, said the drug has been successful at the animal testing stage.
“When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500,” said Xie.
“That means this potential drug has therapeutic effect.”
The drug uses neutralising antibodies — produced by the human immune system to prevent the virus infecting cells — which Xie’s team isolated from the blood of 60 recovered patients.
A study on the team’s research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential “cure” for the disease and shortens recovery time.
Xie said his team had been working “day and night” searching for the antibody.
“Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled.”
He said he hopes that the drug will be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.
“Planning for the clinical trial is underway.
“The hope is these neutralising antibodies can become a specialised drug that would stop the pandemic,” he said.
“We would be able to stop the pandemic with an effective drug, even without a vaccine,” said Xie
China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.
More than 100 vaccines for COVID-19 are in the works globally.
© 2020, https:. All rights reserved., Attribution and link to nigeriamaritime360.com is required if you wish to use any of the articles on this site